
Daptomycin
CAS No. 103060-53-3
Daptomycin( Cubicin | LY146032 )
Catalog No. M10148 CAS No. 103060-53-3
Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 38 | In Stock |
![]() ![]() |
25MG | 56 | In Stock |
![]() ![]() |
50MG | 81 | In Stock |
![]() ![]() |
100MG | 154 | In Stock |
![]() ![]() |
200MG | 244 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameDaptomycin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDaptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
-
DescriptionDaptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.(In Vitro):Daptomycin has excellent in-vitro inhibitory and bactericidal activity against nafcillin-susceptible and resistant staphylococci (MIC90 less than or equal to 0.5 mg/L) and against enterococci (MIC90 less than or equal to 2.0 mg/L). Daptomycin is more active than vancomycin against the majority of isolated tested. With the exception of trimethoprim-sulphamethoxazole, daptomycin is the most active agent in vitro against enterococci, and is the most active against nafcillin-resistant staphylococci. Daptomycin and vancomycin show a marked increase in MIC when the inoculum is increased from 105 to 107 cfu/mL. Daptomycin is effective within a very narrow range of drug concentrations (from 0.125 to 2.0 tLg/mL) and is more active than other agents tested against S. faecalis. Daptomycin inhibits the formation of these nucleotide-linked intermediates.(In Vivo):At a dose of 10 mg/kg given twice daily, daptomycin reduces the number of organisms per kidney significantly compared with that in infected untreated controls within 48 h after the initiation of therapy. At 20 mg/kg given once a day, daptomycin is less effective but reduces colony counts significantly after 4 days of therapy, and its activity is comparable to that of vancomycin or vancomycin-gentamicin given twice daily.
-
In VitroDaptomycin has excellent in-vitro inhibitory and bactericidal activity against nafcillin-susceptible and resistant staphylococci (MIC90 less than or equal to 0.5 mg/L) and against enterococci (MIC90 less than or equal to 2.0 mg/L). Daptomycin is more active than vancomycin against the majority of isolated tested. With the exception of trimethoprim-sulphamethoxazole, daptomycin is the most active agent in vitro against enterococci, and is the most active against nafcillin-resistant staphylococci. Daptomycin and vancomycin show a marked increase in MIC when the inoculum is increased from 105 to 107 cfu/mL. Daptomycin is effective within a very narrow range of drug concentrations (from 0.125 to 2.0 tLg/mL) and is more active than other agents tested against S. faecalis. Daptomycin inhibits the formation of these nucleotide-linked intermediates.
-
In VivoAt a dose of 10 mg/kg given twice daily, daptomycin reduces the number of organisms per kidney significantly compared with that in infected untreated controls within 48 h after the initiation of therapy. At 20 mg/kg given once a day, daptomycin is less effective but reduces colony counts significantly after 4 days of therapy, and its activity is comparable to that of vancomycin or vancomycin-gentamicin given twice daily.
-
SynonymsCubicin | LY146032
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA synthesis
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number103060-53-3
-
Formula Weight1620.68
-
Molecular FormulaC72H101N17O26
-
Purity>98% (HPLC)
-
SolubilityWater: 100 mg/mL (61.7 mM)
-
SMILESO=C1NCC(N[C@@H](CCCN)C(N[C@@H](CC(O)=O)C(N[C@H](C)C(N[C@@H](CC(O)=O)C(NCC(N[C@H](CO)C(N[C@@H]([C@H](C)CC(O)=O)C(N[C@@H](CC(C2=CC=CC=C2N)=O)C(OC(C)C1NC([C@@H](NC([C@@H](NC([C@@H](NC(CCCCCCCCC)=O)CC3=CNC4=C3C=CC=C4)=O)CC(N)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
-
Chemical Name2,2'-((3S,6S,9R,15S,18R,21S,24S)-30-((S)-2-((S)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-aminopropyl)-6-((R)-1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Silverman JA, et al. Antimicrob Agents ChemOthers, 2003, 47(8), 2538-2544.
molnova catalog



related products
-
ZM 39923 hydrochlori...
ZM 39923 hydrochloride is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
-
Hydroxyurea
Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
-
3-O-Acetyl-beta-bosw...
3-O-Acetyl-beta-boswellic acid has antitumor activity, it inhibits synthesis of DNA, RNA and protein in human leukemia HL-60 cells in a dose dependent manner with IC50 values ranging from 0.6 to 7.1 microM.